APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hepatic Encephalopathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatic Encephalopathy Drugs include Umecrine Cognition, Norgine, Mallinckrodt, Lupin, Kannalife Sciences, Kaleido Biosciences, Ferring Pharmaceuticals, Cosmo Pharmaceuticals and Bausch Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hepatic Encephalopathy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatic Encephalopathy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatic Encephalopathy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatic Encephalopathy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatic Encephalopathy Drugs Segment by Company

Umecrine Cognition

Norgine

Mallinckrodt

Lupin

Kannalife Sciences

Kaleido Biosciences

Ferring Pharmaceuticals

Cosmo Pharmaceuticals

Bausch Health

ASKA Pharmaceutical

Hepatic Encephalopathy Drugs Segment by Type

Injection

Oral

Hepatic Encephalopathy Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hepatic Encephalopathy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatic Encephalopathy Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hepatic Encephalopathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hepatic Encephalopathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hepatic Encephalopathy Drugs Industry Trends Table 2. Hepatic Encephalopathy Drugs Industry Drivers Table 3. Hepatic Encephalopathy Drugs Industry Opportunities and Challenges Table 4. Hepatic Encephalopathy Drugs Industry Restraints Table 5. Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hepatic Encephalopathy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hepatic Encephalopathy Drugs Sales by Manufacturers (tons) & (2021-2026) Table 8. Global Hepatic Encephalopathy Drugs Sales Market Share by Manufacturers Table 9. Global Hepatic Encephalopathy Drugs Average Sales Price (US$/kg) of Manufacturers (2021-2026) Table 10. Global Hepatic Encephalopathy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hepatic Encephalopathy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hepatic Encephalopathy Drugs Manufacturers, Product Type & Application Table 13. Global Hepatic Encephalopathy Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatic Encephalopathy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Injection Table 17. Major Manufacturers of Oral Table 18. Global Hepatic Encephalopathy Drugs Sales by Type 2021 VS 2025 VS 2032 (tons) Table 19. Global Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 20. Global Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 21. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2026) Table 22. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2027-2032) Table 23. Global Hepatic Encephalopathy Drugs Revenue by Type 2021 VS 2025 VS 2032 (tons) Table 24. Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (tons) Table 25. Global Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (tons) Table 26. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Pharmacies Table 29. Major Manufacturers of Online Pharmacies Table 30. Major Manufacturers of Retail Pharmacies Table 31. Global Hepatic Encephalopathy Drugs Sales by Application 2021 VS 2025 VS 2032 (tons) Table 32. Global Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 33. Global Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 34. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2026) Table 35. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2027-2032) Table 36. Global Hepatic Encephalopathy Drugs Revenue by Application 2021 VS 2025 VS 2032 (tons) Table 37. Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (tons) Table 38. Global Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (tons) Table 39. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 42. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (tons) Table 43. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2021-2026) Table 44. Global Hepatic Encephalopathy Drugs Sales Forecasted by Region (2027-2032) & (tons) Table 45. Global Hepatic Encephalopathy Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 47. North America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 48. North America Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 49. Europe Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 50. Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 51. Europe Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 52. Asia Pacific Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 53. Asia Pacific Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 54. Asia Pacific Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 55. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (tons) Table 56. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 57. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 58. Global Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Hepatic Encephalopathy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Hepatic Encephalopathy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2027-2032) Table 63. Umecrine Cognition Company Information Table 64. Umecrine Cognition Business Overview Table 65. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio Table 67. Umecrine Cognition Recent Development Table 68. Norgine Company Information Table 69. Norgine Business Overview Table 70. Norgine Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Norgine Hepatic Encephalopathy Drugs Product Portfolio Table 72. Norgine Recent Development Table 73. Mallinckrodt Company Information Table 74. Mallinckrodt Business Overview Table 75. Mallinckrodt Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio Table 77. Mallinckrodt Recent Development Table 78. Lupin Company Information Table 79. Lupin Business Overview Table 80. Lupin Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Lupin Hepatic Encephalopathy Drugs Product Portfolio Table 82. Lupin Recent Development Table 83. Kannalife Sciences Company Information Table 84. Kannalife Sciences Business Overview Table 85. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio Table 87. Kannalife Sciences Recent Development Table 88. Kaleido Biosciences Company Information Table 89. Kaleido Biosciences Business Overview Table 90. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio Table 92. Kaleido Biosciences Recent Development Table 93. Ferring Pharmaceuticals Company Information Table 94. Ferring Pharmaceuticals Business Overview Table 95. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 97. Ferring Pharmaceuticals Recent Development Table 98. Cosmo Pharmaceuticals Company Information Table 99. Cosmo Pharmaceuticals Business Overview Table 100. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 102. Cosmo Pharmaceuticals Recent Development Table 103. Bausch Health Company Information Table 104. Bausch Health Business Overview Table 105. Bausch Health Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Bausch Health Hepatic Encephalopathy Drugs Product Portfolio Table 107. Bausch Health Recent Development Table 108. ASKA Pharmaceutical Company Information Table 109. ASKA Pharmaceutical Business Overview Table 110. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (tons), Price (US$/kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio Table 112. ASKA Pharmaceutical Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Hepatic Encephalopathy Drugs Distributors List Table 116. Hepatic Encephalopathy Drugs Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drugs Product Image Figure 2. Global Hepatic Encephalopathy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drugs Sales (2021-2032) & (tons) Figure 5. Global Hepatic Encephalopathy Drugs Average Price (US$/kg) & (2021-2032) Figure 6. Global Top 5 and 10 Hepatic Encephalopathy Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Injection Image Figure 9. Oral Image Figure 10. Global Hepatic Encephalopathy Drugs Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 11. Global Hepatic Encephalopathy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Hepatic Encephalopathy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (tons) Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Pharmacies Image Figure 17. Online Pharmacies Image Figure 18. Retail Pharmacies Image Figure 19. Global Hepatic Encephalopathy Drugs Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 20. Global Hepatic Encephalopathy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Hepatic Encephalopathy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (tons) Figure 23. Global Hepatic Encephalopathy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 26. North America Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 28. Canada Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 29. Mexico Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 30. Europe Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 31. Europe Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 33. France Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 34. U.K. Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 35. Italy Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 36. Netherlands Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 37. Asia Pacific Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 38. Asia Pacific Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2032) Figure 39. China Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 40. Japan Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 41. South Korea Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 42. Southeast Asia Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 43. India Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 44. Australia Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 45. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 46. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 48. South Africa Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 49. Saudi Arabia Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 50. Turkey Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 51. Argentina Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 52. UAE Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 53. Egypt Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 54. Chile Hepatic Encephalopathy Drugs Sales and Growth Rate (2021-2032) & (tons) Figure 55. Global Hepatic Encephalopathy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Hepatic Encephalopathy Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Hepatic Encephalopathy Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Umecrine Cognition
  • Norgine
  • Mallinckrodt
  • Lupin
  • Kannalife Sciences
  • Kaleido Biosciences
  • Ferring Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Bausch Health
  • ASKA Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hepatic Encephalopathy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hepatic Encephalopathy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hepatic Encephalopathy Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hepatic Encephalopathy Drugs Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drugs Industry Trends
  2. 2.2 Hepatic Encephalopathy Drugs Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drugs Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drugs Industry Restraints
3 Hepatic Encephalopathy Drugs Market by Manufacturers
  1. 3.1 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hepatic Encephalopathy Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hepatic Encephalopathy Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatic Encephalopathy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hepatic Encephalopathy Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Hepatic Encephalopathy Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatic Encephalopathy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatic Encephalopathy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatic Encephalopathy Drugs Tier 1, Tier 2, and Tier 3
4 Hepatic Encephalopathy Drugs Market by Type
  1. 4.1 Hepatic Encephalopathy Drugs Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.2 Global Hepatic Encephalopathy Drugs Sales by Type
  5. 4.2.1 Global Hepatic Encephalopathy Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Hepatic Encephalopathy Drugs Revenue by Type
  9. 4.3.1 Global Hepatic Encephalopathy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2032)
5 Hepatic Encephalopathy Drugs Market by Application
  1. 5.1 Hepatic Encephalopathy Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hepatic Encephalopathy Drugs Sales by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drugs Revenue by Application
  10. 5.3.1 Global Hepatic Encephalopathy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2032)
6 Global Hepatic Encephalopathy Drugs Sales by Region
  1. 6.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatic Encephalopathy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Hepatic Encephalopathy Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hepatic Encephalopathy Drugs Revenue by Region
  1. 7.1 Global Hepatic Encephalopathy Drugs Revenue by Region
  2. 7.1.1 Global Hepatic Encephalopathy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hepatic Encephalopathy Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Hepatic Encephalopathy Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hepatic Encephalopathy Drugs Revenue (2021-2032)
  8. 7.2.2 North America Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hepatic Encephalopathy Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hepatic Encephalopathy Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hepatic Encephalopathy Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hepatic Encephalopathy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Umecrine Cognition
  2. 8.1.1 Umecrine Cognition Company Information
  3. 8.1.2 Umecrine Cognition Business Overview
  4. 8.1.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio
  6. 8.1.5 Umecrine Cognition Recent Developments
  7. 8.2 Norgine
  8. 8.2.1 Norgine Company Information
  9. 8.2.2 Norgine Business Overview
  10. 8.2.3 Norgine Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Norgine Hepatic Encephalopathy Drugs Product Portfolio
  12. 8.2.5 Norgine Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Lupin
  20. 8.4.1 Lupin Company Information
  21. 8.4.2 Lupin Business Overview
  22. 8.4.3 Lupin Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lupin Hepatic Encephalopathy Drugs Product Portfolio
  24. 8.4.5 Lupin Recent Developments
  25. 8.5 Kannalife Sciences
  26. 8.5.1 Kannalife Sciences Company Information
  27. 8.5.2 Kannalife Sciences Business Overview
  28. 8.5.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio
  30. 8.5.5 Kannalife Sciences Recent Developments
  31. 8.6 Kaleido Biosciences
  32. 8.6.1 Kaleido Biosciences Company Information
  33. 8.6.2 Kaleido Biosciences Business Overview
  34. 8.6.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio
  36. 8.6.5 Kaleido Biosciences Recent Developments
  37. 8.7 Ferring Pharmaceuticals
  38. 8.7.1 Ferring Pharmaceuticals Company Information
  39. 8.7.2 Ferring Pharmaceuticals Business Overview
  40. 8.7.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  42. 8.7.5 Ferring Pharmaceuticals Recent Developments
  43. 8.8 Cosmo Pharmaceuticals
  44. 8.8.1 Cosmo Pharmaceuticals Company Information
  45. 8.8.2 Cosmo Pharmaceuticals Business Overview
  46. 8.8.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  48. 8.8.5 Cosmo Pharmaceuticals Recent Developments
  49. 8.9 Bausch Health
  50. 8.9.1 Bausch Health Company Information
  51. 8.9.2 Bausch Health Business Overview
  52. 8.9.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bausch Health Hepatic Encephalopathy Drugs Product Portfolio
  54. 8.9.5 Bausch Health Recent Developments
  55. 8.10 ASKA Pharmaceutical
  56. 8.10.1 ASKA Pharmaceutical Company Information
  57. 8.10.2 ASKA Pharmaceutical Business Overview
  58. 8.10.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio
  60. 8.10.5 ASKA Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatic Encephalopathy Drugs Value Chain Analysis
  2. 9.1.1 Hepatic Encephalopathy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatic Encephalopathy Drugs Production Mode & Process
  6. 9.2 Hepatic Encephalopathy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatic Encephalopathy Drugs Distributors
  9. 9.2.3 Hepatic Encephalopathy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst